Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 285Lymphoma 201Lymphoma, Large B-Cell, Diffuse 167Sarcoma 141Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hodgkin Disease 85Lymphoma, Non-Hodgkin 78Burkitt Lymphoma 67Lymphoma, Follicular 61Leukemia 58Ovarian Neoplasms 50Neoplasms 50Triple Negative Breast Neoplasms 49Lymphoma, Mantle-Cell 48Multiple Myeloma 47Neuroblastoma 44Carcinoma, Hepatocellular 44Neoplasm Metastasis 41Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Recurrence 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Osteosarcoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

niraparib 3Paclitaxel 2Letrozole 2trametinib 1ribociclib 1pembrolizumab 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1Blood Specimen Collection 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cystadenocarcinoma, Serous × Doxorubicin × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡